(Total Views: 622)
Posted On: 01/13/2021 8:03:29 PM
Post# of 145915
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Investing in stocks is about risk assessment/risk control.
The evidence, the trials, our earlier eIND cases, our Phase II m/m trial, the DSMC response to our Phase III s/c interim data, Dr Patterson, Dr Yo, Dr Been.....
I am aware of the good probability that we will get a s/c EUA soon.
Risk assessment.....So if we knew that the FDA could and might grant an EUA if we achieve only "Clinical Signifance", this would reduce our risk, and result in some of us buying more shares of CYDY.
Is there some chance, any chance, a good chance that the FDA could give Leronlimab an EUA if only "Clinical Significance" is achieved? If yes, I will buy more shares, eventhough I am heavily invested already. In fact, CYDY is my only stock. My diversity is that I've bought CYDY at 8 different share prices.
The evidence, the trials, our earlier eIND cases, our Phase II m/m trial, the DSMC response to our Phase III s/c interim data, Dr Patterson, Dr Yo, Dr Been.....
I am aware of the good probability that we will get a s/c EUA soon.
Risk assessment.....So if we knew that the FDA could and might grant an EUA if we achieve only "Clinical Signifance", this would reduce our risk, and result in some of us buying more shares of CYDY.
Is there some chance, any chance, a good chance that the FDA could give Leronlimab an EUA if only "Clinical Significance" is achieved? If yes, I will buy more shares, eventhough I am heavily invested already. In fact, CYDY is my only stock. My diversity is that I've bought CYDY at 8 different share prices.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)